Department of Interventional Radiotherapy, Huzhou Central Hospital, Affiliated Central Hospital Huzhou University, Huzhou, Zhejiang Province, P.R. China.
Eur Rev Med Pharmacol Sci. 2021 Aug;25(16):5090-5103. doi: 10.26355/eurrev_202108_26520.
The aim of the study was to compare the risk of chemotherapy induced alopecia among patients with scalp cooling therapy, compared to those that did not receive scalp cooling.
A systematic search was conducted in the PubMed, Scopus, Cochrane Database of Systematic Reviews and Google scholar databases. Studies, preferably randomized controlled trials, that compared scalp cooling with no scalp cooling (control) for risk of alopecia or hair loss in patients undergoing chemotherapy were considered for inclusion. The strength of association was presented in the form of pooled adjusted relative risk (RR) for categorical outcomes and weighted mean difference (WMD) for continuous outcomes. Statistical analysis was done using STATA version 16.0.
A total of 14 articles were identified, of which 9 were included in the meta-analysis and for the remaining 5 articles, the findings were synthesized descriptively. Compared to control group patients, those that received scalp cooling had 41% lower risk of alopecia [RR 0.59, 95% CI: 0.53, 0.66]. The overall quality of pooled evidence for the risk of alopecia was judged "moderate". There were no differences in the anxiety score [WMD 0.57, 95% CI: -0.55, 1.69], depression score [WMD 0.31, 95% CI: -1.19, 1.80], score reflecting emotional functioning [WMD 0.06, 95% CI: -1.37, 1.49] and social functioning [WMD -8.37, 95% CI: -25.7, 8.93] among the two groups of patients. The pooled evidence suggests that around 66% (95% CI: 37-95%) of the subjects reported some discomfort with use of scalp cooling system. The commonly reported complaints included headache, scalp and neck pain, discomfort due to chill, nausea/vomiting and dizziness.
Findings suggest that the use of scalp cooling, compared to no scalp cooling, reduces the risk of significant hair loss. The acceptability of this cooling system might be limited by a high incidence of reported complaints.
本研究旨在比较头皮冷却疗法与未接受头皮冷却的患者在化疗引起脱发风险方面的差异。
在 PubMed、Scopus、Cochrane 系统评价数据库和 Google 学术数据库中进行系统检索。纳入比较头皮冷却与不进行头皮冷却(对照组)对接受化疗的患者脱发或头发稀疏风险的研究,优选为随机对照试验。采用汇总调整后相对风险(RR)表示分类结局,加权均数差(WMD)表示连续结局的关联强度。使用 STATA 版本 16.0 进行统计分析。
共确定了 14 篇文章,其中 9 篇纳入了荟萃分析,对于其余 5 篇文章,进行了描述性综合分析。与对照组患者相比,接受头皮冷却的患者脱发风险降低了 41%[RR 0.59,95%CI:0.53,0.66]。头皮冷却对脱发风险的汇总证据质量总体评价为“中等”。两组患者的焦虑评分[WMD 0.57,95%CI:-0.55,1.69]、抑郁评分[WMD 0.31,95%CI:-1.19,1.80]、情绪功能评分[WMD 0.06,95%CI:-1.37,1.49]和社会功能评分[WMD-8.37,95%CI:-25.7,8.93]均无差异。汇总证据表明,约 66%(95%CI:37%-95%)的患者报告使用头皮冷却系统存在一些不适。常见的不良反应包括头痛、头皮和颈部疼痛、寒冷不适、恶心/呕吐和头晕。
研究结果表明,与不使用头皮冷却相比,使用头皮冷却可降低严重脱发的风险。但由于头皮冷却系统的不良反应发生率较高,其可接受性可能受到限制。